An emerging entity: Pancreatic adenocarcinoma associated with a known brca mutation: Clinical descriptors, treatment implications, and future directions Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Genes, BRCA1
  • Genes, BRCA2
  • Germ-Line Mutation
  • Pancreatic Neoplasms

abstract

  • BRCA mutation-associated PAC represents an underidentified, but clinically important, subgroup of patients. This is of particular relevance given the ongoing development of therapeutic agents targeting DNA repair, which may potentially offer a significant benefit to a genetically selected population. We anticipate that further study and understanding of the clinical and biologic features of BRCA-mutant PAC will aid in the identification of tissue biomarkers indicating defective tumor DNA repair pathways in sporadic PAC.

publication date

  • October 26, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3228075

Digital Object Identifier (DOI)

  • 10.1634/theoncologist.2011-0185

PubMed ID

  • 21934105

Additional Document Info

start page

  • 1397

end page

  • 402

volume

  • 16

number

  • 10